NEW YORK, May 18, 2017 /PRNewswire/ --
Biotechnology firms are among the most research-intensive organizations inthe world. Their product pipelines, a vital component of expansion, are capital intensive. Pre-market today, Stock-Callers.com takes a closer look at the most recent performances of Auris Medical Holding AG (NASDAQ: EARS), Eleven Biotherapeutics Inc.
On Wednesday, shares in Zug, Switzerland headquartered Auris Medical Holding AG recorded a trading volume of 114,073 shares. The stock ended flat at $0.66. The Company's shares are trading below their 50-day moving average by 16.46%. Furthermore, shares of Auris Medical, which focuses on the development of novel products for the treatment of inner ear disorders, have a Relative Strength Index (RSI) of 29.74.
On May 09th, 2017, Auris Medical announced key results from AMPACT1 (AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1), the open-label extension study of the Phase 3 TACTT2 clinical trial. The study provides additional confirmation on the long-term safety of Keyzilen® and suggests the potential for further therapeutic benefits from repeated treatment. Access our complete research report on EARS for free at:
Cambridge, Massachusetts-based Eleven Biotherapeutics Inc.'s stock finished yesterday's session 7.32% lower at $1.52. A total volume of 422,851 shares was traded, which was above their three months average volume of 419,820 shares. The Company's shares are trading below their 50-day moving average by 21.64%. Furthermore, shares of Eleven Biotherapeutics, which focuses on the design and development of targeted protein therapeutics, have an RSI of 24.34.
On May 04th, 2017, Eleven Biotherapeutics reported financial results for the quarter ended March 31st, 2017. Revenue was $0.4 million for Q1 2017; net loss was $6.1 million; R&D expenses were $2.9 million; general and administrative expenses were $2.2 million; and cash and cash equivalents were $20.3 million. In addition, the Company expects to have cash to fund research and development programs and operations into early 2018, based on current operating plans. The complimentary research report on EBIO can be downloaded at:
At the close of trading on Wednesday, shares in Lexington, Massachusetts headquartered Inotek Pharmaceuticals Corp. saw a decline of 5.41%, ending the day at $1.75. The stock recorded a trading volume of 318,300 shares. The Company's shares have advanced 7.69% in the previous three months. The stock is trading 6.27% below its 50-day moving average. Moreover, shares of Inotek Pharma, which focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the US, have an RSI of 44.67.
On May 10th, 2017, Inotek Pharma reported financial results and operational highlights for the quarter ended March 31st, 2017. R&D expenses were $7.1 million for Q1 2017; general and administrative expenses were $2.9 million; loss from operations was $10.0 million; and net loss was $10.7 million. The Company also reported cash and cash equivalents and short-term investments of $114.7 million as of March 31st, 2017. Register for free on Stock-Callers.com and get access to the latest PDF format report on ITEK at:
Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.'s shares ended the day 3.85% lower at $1.25 with a total trading volume of 208,878 shares. The stock has gained 23.76% on an YTD basis. The Company's shares are trading 8.90% below their 200-day moving average. Additionally, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 36.40.
On May 01st, 2017, Marinus Pharmaceuticals reported its financial results for the quarter ended March 31st, 2017. R&D expenses for Q1 2017 decreased to $3.6 million; general and administrative expenses increased to $1.8 million; and cash used in operating activities increased to $6.8 million. Additionally, the Company had cash, cash equivalents, and investments of $24.8 million at March 31st, 2017. Download your free research report on MRNS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All